Structured evidence table for Bifidobacterium Breve Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Bifidobacterium Breve Cognition Randomized Trial | The pooled Repeatable Battery for the Assessment of Neuropsychological Status result was not statistically significant ( g = 0.46; 95% CI: -0.50 to 1.41). | 1 | Silva-Olivares F (2026) | Can live microbial interventions support healthy aging? A systematic review and meta-analysis of cognitive and muscle outcomes in aging adults. |
| Bifidobacterium Breve Cognition Randomized Trial | Discussion Live microorganism-based interventions showed preliminary short-term functional signals, but the small evidence base, high cognitive heterogeneity, short follow-up, and sensitivity to individual studies preclude firm efficacy conclusions. | 1 | Silva-Olivares F (2026) | Can live microbial interventions support healthy aging? A systematic review and meta-analysis of cognitive and muscle outcomes in aging adults. |
| Bifidobacterium Breve Cognition Randomized Trial | No eligible fecal microbiota transplantation trial was identified, so the evidence derives exclusively from probiotic and synbiotic studies. | 1 | Silva-Olivares F (2026) | Can live microbial interventions support healthy aging? A systematic review and meta-analysis of cognitive and muscle outcomes in aging adults. |
| Bifidobacterium Breve Cognition Randomized Trial | Introduction Preserving cognitive and physical function is central to healthy aging, and the gut microbiota may influence both brain and muscle physiology. | 1 | Silva-Olivares F (2026) | Can live microbial interventions support healthy aging? A systematic review and meta-analysis of cognitive and muscle outcomes in aging adults. |
| Bifidobacterium Breve Cognition Randomized Trial | There is mounting evidence that the gut microbiome (GM) and microbial dysbiosis contribute to the common mental health and neurocognitive disorders, including anxiety, bipolar disorder, obsessive‐compulsive disorder, and dementia, via the gut‐brain axis (GBA). | 3 | Mandloi Nidhi (2026) | Serotonin neuromicrobiology: Psychobiotic modulation of the gut–brain axis for mental health |
| Bifidobacterium Breve Cognition Randomized Trial | In addition, pro‐inflammatory cytokines decrease the serotonin level, which leads to psychological disorders, such as anxiety and depression, and a consequent decrease in the host immunity.Change in GM as a result of consumption of psychobiotics causes a variety of changes, including nervous, endocrine, and immune responses by affecting a person's cognitive, mood, and behavioral reactivity. | 3 | Mandloi Nidhi (2026) | Serotonin neuromicrobiology: Psychobiotic modulation of the gut–brain axis for mental health |
| Bifidobacterium Breve Cognition Randomized Trial | A placebo‐controlled trial also showed that depressive symptoms significantly improved in thePS128‐treated patients, with the symbiosis of specific microbial taxa.These studies have shown that the GM plays a key role in regulating brain activity and cognition. | 3 | Mandloi Nidhi (2026) | Serotonin neuromicrobiology: Psychobiotic modulation of the gut–brain axis for mental health |
| Bifidobacterium Breve Cognition Randomized Trial | Over a billion individuals worldwide suffer from mental and addictive disorders, which account for 7% of the global disease burden, and this burden rises as people age.According to the World Mental Health Report, around 1.095 billion people worldwide, approximately one in seven, are afflicted with mental illnesses, indicating a startling burden of mental health issues. | 3 | Mandloi Nidhi (2026) | Serotonin neuromicrobiology: Psychobiotic modulation of the gut–brain axis for mental health |
Source documents